emerging glp-1 gip obesity treatments 2025 Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports GLP-1 Antagonists Increase Plan Drug

As with any injectable, there is a risk of allergic reaction or interaction with certain medications

The pressure to bounce back can be relentless, and that pressure often gets internalized

The SELECT trial demonstrated that semaglutide 2.4 mg weekly reduced cardiovascular events in adults with established cardiovascular disease and either overweight or obesity

GLP-1 receptor agonists work by mimicking a natural hormone that helps regulate blood sugar, control appetite, and support weight loss

Collectively, these engineering strategies not only improve the accumulation of MEVs at disease sites but also enhance drug delivery efficiency through receptor-mediated endocytosis, while largely preserving their inherent low immunogenicity